Table 3 Incidence of non-hematological toxicities grade 3 and 4 by randomization

From: Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study

Treatment arm All randomized and evaluable patients in the study
Total patients Standard S-HAM
n/N (%) n/N (%) n/N (%)
Alopecia 141/259 (54.4) 70/132 (53.0) 71/127 (56.0)
Infection 166/349 (47.6) 80/181 (44.2) 86/168 (51.2)
Pulmonary toxicity 66/352 (18.8) 28/181 (15.5) 38/171 (22.2)
Prothrombin 17/281 (6.0) 6/149 (4.0) 11/132 (8.3)
Fever 45/353 (12.7) 26/183 (14.2) 19/170 (11.2)
Diarrhea 39/352 (11.1) 17/181 (9.4) 22/171 (12.9)
Pain 55/351 (15.7) 22/180 (12.2) 33/171 (19.3)
Nausea/vomiting 31/351 (8.8) 16/180 (8.9) 15/171 (8.8)
PCHE 3/209 (1.4) 1/110 (0.9) 2/99 (2.0)
Hypoproteinemia 30/296 (10.1) 15/151 (9.9) 15/145 (10.3)
Mucositis 22/344 (6.4) 5/177 (2.8) 17/167 (10.2)
Weight gain 43/352 (12.2) 22/183 (12.0) 21/169 (12.4)
Cardiac function 12/346 (3.5) 8/179 (4.5) 4/167 (2.4)
Bleeding 25/350 (7.1) 8/183 (4.4) 17/167 (10.2)
SGOT/SGPT 37/351 (10.5) 18/180 (10.0) 19/171 (11.1)
Central nervous system 18/349 (5.2) 5/179 (2.8) 13/170 (7.7)
Bilirubin 16/352 (4.5) 6/181 (3.3) 10/171 (5.9)
Effusion 17/350 (4.9) 8/180 (4.4) 9/170 (5.3)
Edema 21/350 (6.0) 8/179 (4.5) 13/171 (7.6)
Cutaneous toxicity 8/348 (2.3) 2/181 (1.1) 6/167 (3.6)
Alkaline phosphatase 4/306 (1.3) 2/156 (1.3) 2/150 (1.3)
Cardiac rhythm 7/344 (2.0) 3/180 (1.7) 4/164 (2.4)
Creatinine/renal toxicity 3/352 (0.9) 3/181 (1.7) 0/171 (0.0)
Obstipation 5/351 (1.4) 2/181 (1.1) 3/170 (1.8)
Hematuria 1/347 (0.3) 1/179 (0.6) 0/168 (0.0)
Extrapyramidal symptoms 4/350 (1.1) 2/180 (1.1) 2/170 (1.2)
Allergic reaction 2/346 (0.6) 1/181 (0.6) 1/165 (0.6)
Peripheral nervous system 3/351 (0.9) 2/181 (1.1) 1/170 (0.6)
Pericarditis 0/346 (0.0) 0/178 (0.0) 0/168 (0.0)